JP2023542296A - Fgfr阻害剤の併用療法 - Google Patents

Fgfr阻害剤の併用療法 Download PDF

Info

Publication number
JP2023542296A
JP2023542296A JP2023516479A JP2023516479A JP2023542296A JP 2023542296 A JP2023542296 A JP 2023542296A JP 2023516479 A JP2023516479 A JP 2023516479A JP 2023516479 A JP2023516479 A JP 2023516479A JP 2023542296 A JP2023542296 A JP 2023542296A
Authority
JP
Japan
Prior art keywords
inhibitor
alteration
gene
patient
fgfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542296A5 (cg-RX-API-DMAC7.html
Inventor
サンティアゴ-ウォーカー,アデミ,エレナ
モイ,クリストファー,エイチ.
Original Assignee
ヤンセン ファーマシューティカ エヌ.ベー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ.ベー. filed Critical ヤンセン ファーマシューティカ エヌ.ベー.
Publication of JP2023542296A publication Critical patent/JP2023542296A/ja
Publication of JP2023542296A5 publication Critical patent/JP2023542296A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023516479A 2020-09-14 2021-09-13 Fgfr阻害剤の併用療法 Pending JP2023542296A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078193P 2020-09-14 2020-09-14
US63/078,193 2020-09-14
PCT/EP2021/075145 WO2022053697A1 (en) 2020-09-14 2021-09-13 Fgfr inhibitor combination therapies

Publications (2)

Publication Number Publication Date
JP2023542296A true JP2023542296A (ja) 2023-10-06
JP2023542296A5 JP2023542296A5 (cg-RX-API-DMAC7.html) 2024-09-26

Family

ID=77821784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516479A Pending JP2023542296A (ja) 2020-09-14 2021-09-13 Fgfr阻害剤の併用療法

Country Status (10)

Country Link
US (1) US20230321087A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210702A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542296A (cg-RX-API-DMAC7.html)
KR (1) KR20230069958A (cg-RX-API-DMAC7.html)
CN (1) CN116669763A (cg-RX-API-DMAC7.html)
AU (1) AU2021339962A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191538A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002980A (cg-RX-API-DMAC7.html)
TW (1) TW202228695A (cg-RX-API-DMAC7.html)
WO (1) WO2022053697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO2005110076A2 (en) 2004-05-10 2005-11-24 Children's Medical Center Corporation Braf expression in zebrafish and uses thereof
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
EA201792205A1 (ru) * 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
MA43416A (fr) * 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
WO2018213297A1 (en) * 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
KR20250047324A (ko) * 2017-08-07 2025-04-03 더 존스 홉킨스 유니버시티 암을 평가하고 치료하기 위한 방법 및 재료
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
US20220175768A1 (en) * 2019-03-29 2022-06-09 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
WO2020208592A1 (en) * 2019-04-12 2020-10-15 Dr. Reddy’S Laboratories Limited Process for preparation of erdafitinib, its purification and amorphous solid dispersion
CN111420060B (zh) * 2020-03-30 2022-04-08 南方医科大学南方医院 一种抗肿瘤的联合用药组合物及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. 66, no. 23, JPN6026019917, 2006, pages 11389 - 11398, ISSN: 0005868894 *
CLIN CANCER RES, vol. 10, JPN6026019918, 2004, pages 7764 - 7774, ISSN: 0005868893 *
HAURA ERIC B ET AL: "ERDAFITINIB OVERCOMES FGFR3-TACC3-MEDIATED RESISTANCE TO OSIMERTINIB", JOURNAL OF THORACIC ONCOLOGY, vol. VOL.15, NR.9, JPN5024007325, 24 August 2020 (2020-08-24), US, pages 154 - 156, ISSN: 0005868891 *
M T HERRERA-ABREU ET AL: "PARALLEL RNA INTERFERENCE SCREENS IDENTIFY EGFR ACTIVATION AS AN ESCAPE MECHANISM IN FGFR3-MUTANT CA", CANCER DISCOVERY, vol. VOL.3, NR.9, JPN5024007326, September 2013 (2013-09-01), US, pages 1058 - 1071, ISSN: 0005868892 *

Also Published As

Publication number Publication date
CN116669763A (zh) 2023-08-29
US20230321087A1 (en) 2023-10-12
WO2022053697A1 (en) 2022-03-17
KR20230069958A (ko) 2023-05-19
TW202228695A (zh) 2022-08-01
MX2023002980A (es) 2023-06-06
CA3191538A1 (en) 2022-03-17
EP4210702A1 (en) 2023-07-19
AU2021339962A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
AU2018246873B2 (en) ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
ES3041987T3 (en) Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
KR20220133243A (ko) 항 tigit 길항제 항체를 이용한 암의 치료 방법
CN111492245A (zh) 癌症的治疗和诊断方法
TW201819640A (zh) 癌症之治療性及診斷性方法
JP2018518483A (ja) 抗ox40抗体及びpd−1軸結合アンタゴニストを使用して癌を治療する方法
CA2943834A1 (en) Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US20240424092A1 (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
US10857230B2 (en) Co-therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer
AU2018389196A1 (en) Methods and combination therapy to treat cancer
US20240026029A1 (en) Means and methods for treating subjects with erbb3 mutation positive cancer
TWI900527B (zh) 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
US20230070988A1 (en) Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer
CN116568326A (zh) 用于治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物
EP4476255A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
US20230321087A1 (en) Fgfr inhibitor combination therapies
WO2026038160A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
WO2023138574A1 (zh) 螺环芳基磷氧化物与抗vegf抗体的药物组合
WO2024121163A1 (en) Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers
HK40110052A (en) Methods and compositions for treating cancer
CN114470190A (zh) 喹啉衍生物与pd-1单抗的药物组合
HK40085445A (en) Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260526